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A number of different proteases and their inhibitors
have a role in skin physiology and in the pathophys-
iology of inflammatory skin diseases. Proteases are
important in the desquamation process and orderly
regulation of the skin’s barrier function. On the basis
of the catalytic domain, proteases are classified into
aspartate-, cysteine-, glutamate-, metallo-, serine-, and
threonine proteases. Particularly, serine proteases
(SPs) contribute to epidermal permeability barrier
homeostasis, as acute barrier disruption increases SP
activity in skin and inhibition by topical SP inhibitors
accelerated recovery of barrier function after acute
abrogation. In rosacea, increased levels of the vasoac-
tive and inflammatory host-defense peptide cathelici-
din LL-37 and its proteolytic peptide fragments were
found, which were explained by an abnormal produc-
tion of tryptic activity originating from kallikrein-
related peptidase (KLK) 5. It is therefore possible that
also other proteases, even from microbial or parasite
origin, have a role in rosacea by forming alternate
angiogenic and proinflammatory cathelicidin pep-
tides. Further, the regulation of protease activity, in
particular KLK-5 activity, might have a role in rosacea.
This review briefly summarizes our current knowl-
edge about keratinocyte-derived proteases and pro-
tease inhibitors, which might have a role in the
pathophysiology of rosacea.
Journal of Investigative Dermatology Symposium Proceedings (2011) 15,
16–23; doi:10.1038/jidsymp.2011.2
INTRODUCTION
Although rosacea is one of the most frequent inflammatory
skin disease, its pathophysiology is not understood yet.
Recent findings suggest that proteolytically generated pro-
ducts mediate many of the pathological changes in rosacea.
Most interestingly, these enzymatic processes were identified
to contribute to epithelial barrier homeostasis and are directly
involved in other inflammatory skin diseases. This review will
summarize the various proteases and their inhibitors involved
in epidermal barrier function and will try to relate their
function at the end to the development of rosacea.
PROTEASES
The formation of stratified epithelia requires a specific
differentiation program, which includes a timely and spatially
well-coordinated proteolytic system to detach the corneo-
cytes from each other without any disturbance of the barrier
function. A number of different proteases and their inhibitors
have been involved in the desquamation process and
demonstrated to contribute to the skin’s barrier function.
On the basis of the catalytic domain, proteases are classified
into aspartate-, cysteine-, glutamate-, metallo-, serine-, and
threonine proteases. Particularly serine proteases (SPs) have a
prominent role in epidermal permeability barrier homeo-
stasis, as acute barrier disruption increases SP activity in skin
and inhibition by topical SP inhibitors accelerated recovery
of barrier function after acute abrogation (Hachem et al.,
2006).
Cysteine-, aspartate-, and metallo proteases
Cysteine peptidases represent phylogenetically ubiquitous
enzymes, which can be classified into clans of independent
proteins (based on the structural organization of the active
site). Two of the major clans in mammalian genomes are the
‘‘CA’’ clan, where members share an evolutionary and
structural history with papain, and the ‘‘CB’’ clan, which
includes the caspases and the legumains.
One of the most skin-relevant caspases is the cysteinyl-
aspartate protease caspase-14 (Demerjian et al., 2008). In
contrast to other ubiquitously expressed members of the
caspase family, caspase-14 is rather specifically expressed
within the epidermis, where it is of high importance in the
formation of the physical skin barrier. It is expressed in the
keratinocytes (KCs) of the uppermost stratum granulosum
(SG), where it was found to be associated with the nucleus,
the keratohyalin granules, and the desmosomes. Although its
localization suggested a role for nuclear degradation during
cornification, in caspase-14-deficient mice, nuclear degrada-
tion was not affected. The observation that caspase-14 has
only been found in terrestrial mammals but not in birds or
reptiles, and that profilaggrin is a direct substrate of caspase
14, suggests that it is important for the formation of a soft
stratum corneum (SC). This could indicate a coevolution of a
soft SC and the caspase-14 gene (Denecker et al., 2007).
Caspase-14 is produced as procaspase within the SG, where
it maturates in cornified epithelia. Although it is not clear
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how it maturates, most likely a SP with elastase-like proper-
ties could be involved (Denecker et al., 2008). Thus, caspase-
14 seems to be involved in the correct processing of
profilaggrin, preceding its degradation into hygroscopic
amino acids, as well as the formation of ultraviolet
B-protective compounds.
Recently, it was reported that chronic loss of epidermal
caspase-8 results in the development of an atopic-like disease
in mice (Li et al., 2010). Conditional caspase-8 knockout
mice exhibited increased metalloproteinase-2 activity and a
phenotype similar to atopic dermatitis. Metalloproteinases
are thought to contribute mainly to wound-healing processes,
but their effects are also important for epithelial barrier
function.
Another skin cysteine peptidase is cathepsin C, which
represents a lysosomal cysteine peptidase of the papain family
CIA, which is important for intracellular degradation, and which
has a role in the activation of SPs in immune cells (Rao et al.,
1997). Cathepsin C knockout mice indicated that activation and
processing of granzymes A and B, which are important for
T-cell-mediated cell killing, depends on cathepsin C (Pham and
Ley, 1999). Interestingly, cathepsin C deficiency in humans
leads to a marked reduction of both levels and activities of the
neutrophil SPs elastase, protease-3, and cathepsin G (Pham
et al., 2004), which will be described below.
Cathepsin D represents the main aspartic protease of
endolysosomes. It is active at the physiological acidic pH of
healthy skin and is of relevance in the desquamation process
(Horikoshi et al., 1999). Cathepsin D knockout mice showed
reduced levels of involucrin and loricrin and lower transglu-
taminase 1 activity, which indicates that cathepsin D
contributes indirectly to the barrier function of human skin
(Egberts et al., 2004).
Serine proteases
Serine proteases represent a family of enzymes that use a
catalytic triad in the substrate-binding pocket (Ser, His, Asp)
to cleave peptide bonds. On the basis of their substrate
specificity, these proteases can be subdivided into trypsin-like
enzymes (cleaves C-terminally of Arg and Lys), chymotryptic
enzymes (cleave behind aromatic or bulky, hydrophobic
amino acids), and the elastase-like enzymes (cleave behind
small or medium size non-polar amino acids). These enzymes
have an important role in the terminal differentiation process
and desquamation.
Matriptase and prostasin
One of the most important factors in epidermal barrier
function is profilaggrin. It is processed at the SG/SC
interphase to filaggrin monomers. These are crosslinked to
form macrofibrils and eventually ‘‘natural moisturizing
factors’’, which are important for maintaining the hydration
of the SC (reviewed in Ovaere et al. 2009). The importance of
profilaggrin proteolysis to maintain epidermal structure and
hydration has been underscored by human genetic studies.
These have shown that loss-of-function mutations in profilag-
grin cause ichthyosis vulgaris and are strongly predisposing to
atopic dermatitis and asthma, possibly due to a disturbed
epidermal barrier function, which allows entry of allergens
and infectious agents (Sandilands et al., 2006).
Major proteases required for initiating profilaggrin proces-
sing are the type II transmembrane SP matriptase and
prostasin, a glycosyl-phosphatidylinositol-anchored mem-
brane SP. There is now evidence that the autoactivating
protease matriptase functions upstream of prostasin in a
zymogen activation cascade that regulates terminal epider-
mal differentiation and is required for prostasin zymogen
activation (Netzel-Arnett et al., 2006). A reduced matriptase
expression was shown to be associated with incomplete
terminal differentiation of the epidermis, epidermal append-
ages, and oral epithelium (Bugge et al., 2007). Matriptase
gene mutations lead to ichthyosis as recently reported (Alef
et al., 2008). Matriptase is immediately activated by exposure
to an acidic pH, as it occurs in skin, suggesting that
matriptase activation may be a direct response to proton
exposure (Tseng et al., 2010). Recent evidence showed that
during epidermal differentiation, the matriptase–prostasin
proteolytic cascade is tightly regulated by two mechanisms,
either by prostasin activation temporally coupled to matrip-
tase autoactivation or by the hepatocyte growth factor
activator inhibitor-1, which is rapidly inhibiting not only
active matriptase but also active prostasin, resulting in an
extremely brief window of opportunity for both active
matriptase and active prostasin to function on their substrates
(Chen et al., 2010). Until now, these two membrane-bound
proteases are thought to be mainly involved in skin homeo-
stasis. However, the ability of matriptase to activate
kallikrein-related (KLKs) proteases in the skin points to a
regulatory role of matriptase in inflammatory skin diseases
(Sales et al., 2010).
Kallikrein-related peptidases
Kallikrein-related proteases are the largest family of tryptic
and chymotryptic SPs, which are encoded by 15 genes on
chromosome 19q13.4. In skin, KLKs are produced by KCs of
the SG, where they are released into interstices of the upper
SG and lower SC. To date, SP activity of SC is attributed to
human tissue KLKs (Borgono et al., 2007). At least eight KLKs
have been reported to be expressed in healthy skin, of which
KLK5, KLK7, KLK8, and KLK14 seem to be the most important
(reviewed in Lundwall and Brattsand, 2008). Their putative
function has been extensively studied (reviewed in Eissa and
Diamandis, 2008; Lundwall and Brattsand, 2008). A wealth
of literature revealed proteolytic function of the two SPs,
KLK5 and KLK7, in SC. These proteases, previously termed as
‘‘stratum corneum tryptic enzyme,’’ (KLK5), and ‘‘stratum
corneum chymotryptic enzyme,’’ (KLK7), have an important
role in the desquamation process, as it was shown that SP
inhibitors were able to inhibit corneocyte shedding from
human plantar skin ex vivo (Lundstrom and Egelrud, 1988).
Both enzymes are maximally expressed in the SG, where they
are released from lamellar bodies and located within the SC
interstices. Here they are thought to form a proteolytic
cascade in which KLK5 activates itself as well as KLK7
(Ovaere et al., 2009). Once active, both enzymes are
believed to digest in vivo corneodesmosin, DSG1, and
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desmocollin-1, as these substrates have been shown to be
digested in vitro. There is now evidence that also other KLKs
participate in desquamation. It was recently shown that
KLK14 is responsible for 50% of the total trypsin-like SP
activity in the SC. Because KLK14 can activate and be
activated by KLK5, it is very likely that it also participates in
the cascade pathway.
Apart from these three KLKs, also KLK8 seems to be
involved in a proteolytic activation cascade regulating skin
desquamation: KLK8 is abundantly expressed and coloca-
lized with other KLKs in human epidermis and sweat glands.
It is also transported and exocytosed by lamellar bodies into
the SG/SC interface, and thus may have a role in SC barrier
functions. Very recent studies showed that recombinant KLK8
is optimally active at pH 8.5, suggesting that it has a role in
the upper SG where the pH is rather neutral (Eissa et al.,
2011). Active KLK8 has been found in SC extracts and in
sweat, where, until recently, only KLK1 and kininase II were
identified as active SPs. This raises its potential functional
involvement in skin desquamation, although the physiologi-
cal substrates need to be identified.
Proteases of bacterial, fungal, and parasite origin
Apart from proteases produced by KCs during differentiation
and desquamation, the SC might also contain extracellular
proteases originating from microbes and/or parasites residing
at the skin surface. Bacterial proteases are often accessory
proteins, which are not fundamental for cell growth and
division, but are considered to be virulence factors, which are
often associated with mobile genetic elements such as
plasmids, integrated phages, and pathogenic islands. The
clustering of bacterial protease genes in operons allows their
coordinated expression, which in turn may imply a coopera-
tion of the produced proteins (Wladyka and Pustelny, 2008).
Staphylococci produce a number of extracellular pro-
teases, e.g., epidermolytic toxins, staphylococcal SPs such as
a glutamyl endopeptidase referred to as V8, and a cysteine
protease in S. aureus. Similar and other proteases are
produced by skin-relevant bacteria, including commensal
S. epidermidis, S. pyogenes, Pseudomonas aeruginosa, and
others (Wladyka and Pustelny, 2008). Among the proteases,
SPs, cysteine proteases, and metalloproteases represent the
most abundant bacterial proteases. These affect the host’s
innate immune system in a bacterial species-specific manner
by targeting phagocytes, cytokines, and cytokine receptors,
inflammatory signaling pathways, complement, contact
activation, as well as antimicrobial peptides (Potempa and
Pike, 2009).
Apart from bacteria, fungi represent an important source of
proteases as well. Upon fungal infections, which are mostly
seen at mucosal surfaces, Candida albicans represents the most
common fungal pathogen. Candida species are ubiquitous
commensal yeasts that reside as part of the normal mucosa
microflora without causing infections. Suitable predisposing
conditions will let C. albicans change to a ‘‘pathogenic’’ stage,
in which proteases represent major virulence factors. These are
exclusively secreted aspartyl proteases (Naglik et al., 2004).
It is believed that extracellular proteases of saprophytic
microorganisms are primarily secreted to obtain nutrients from
decomposition of complex materials. There is, however, strong
evidence that secreted aspartyl proteases are also needed for
invasion of the host, thereby, interacting with several important
host-defense functions eventually causing inflammation
(Naglik et al., 2004).
Proteolysis is also a vital element for survival of parasites,
which enables them to digest resistant structural proteins. For
example, house dust mites (Dermatophagoides pteronyssinus
and D. farinae) produce cysteine proteases and SPs (Donnelly
et al., 2006), which are well known as ‘‘group 1 house dust
mite allergens’’ to induce allergic reactions. Several reports
have shown that these proteases interact with pathways of the
innate defense system, suggesting that these might also be
directly involved in inflammatory skin reactions.
Neutrophil proteases
Upon skin infection or at conditions causing ‘‘neutrophilic
dermatoses’’, the primary cell infiltrate consists of neutro-
phils. A massive infiltrate in the epidermis can lead to
pustule formation. Upon infection, neutrophils phagocytose
microbes and then kill these microbes within the phagolyso-
some by oxygen radical-generating systems, the alpha-
defensins, as well as proteases, which are released from
primary (‘‘azurophilic’’) and secondary (‘‘specific’’) granules
(Faurschou and Borregaard, 2003). Only primary granules
contain high amounts of the SPs such as human leukocyte
elastase, cathepsin G, and protease 3. These enzymes are not
released upon phagocytosis. But upon ‘‘frustrating phagocy-
tosis’’ (attempts to phagocytose particles that are bigger than
leukocytes) and formation of ‘‘neutrophil extracellular traps’’,
consisting of neutrophil-derived DNA, where these cationic
enzymes are bound (Brinkmann et al., 2004), a release of
these enzymes can occur. Indeed, human leukocyte elastase
activity is present at the surface of lesional skin of patients
with psoriasis, a neutrophilic dermatosis (Wiedow et al.,
1992). Neutrophil SPs have been identified as important
innate immune regulators (Meyer-Hoffert, 2009a; Meyer-
Hoffert and Wiedow, 2011). Thus, neutrophil-derived
enzymes may further determine the outcome of an inflam-
matory skin lesion independent of possible homeostasis of
KC-derived proteases and protease inhibitors.
PROTEASE INHIBITORS
Proteolytic activity in the skin, which is often restricted to a
few target proteins, its tissue localization, and its enzymatic
activity need to be properly controlled in the tissue. Although
gene expression and zymogen activation are important
regulatory elements to restrict enzymatic activity, the most
important one is the expression of more or less specific
protease inhibitors within the skin. These inhibitors regulate
the activity of diverse proteases, more or less protease-
specifically, in a time and concentration-dependent manner.
Kazal-type-related protease inhibitors
The ‘‘lympho-epithelial Kazal-type-related inhibitor’’ (LEKTI,
at present named LEKTI-1) is an effective inhibitor of multiple
SPs (Roelandt et al., 2009). Processing of this multidomain
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protease inhibitor into fragments or single domains restricts
the inhibitory properties to SPs such as trypsin, plasmin,
subtilisin A, cathepsin G, and human neutrophil elastase.
LEKTI-1 consists of 15 complete or incomplete Kazal
domains. In vitro, recombinant LEKTI-1 fragments or single
domains inhibit the KC-derived SPs KLK5, -6, -7, -13, and -14.
LEKTI-1 is expressed in various stratified epithelia as three
splice variants. In the epidermis, LEKTI-1 is expressed in the
SG, where LEKTI-1 protein is located in lamellar bodies—
separate from KLKs, but secreted into the extracellular space
together (Ishida-Yamamoto et al., 2004, 2005). The 145-kDa
form comprises all 15 potential inhibitory Kazal domains, but
it is cleaved rapidly into multidomain fragments, which might
be cleaved further to produce single domains and complexes
with KLK5 and KLK7 in the SC. These complexes dissociate at
acidic pH, which because of a pH gradient within the SC may
lead to a controlled homeostatic desquamation. Mutations in
Spink5 (which encodes LEKTI-1) generates premature termi-
nation codons, as seen in Netherton syndrome (Chavanas
et al., 2000), result in expression of truncated LEKTI forms
lacking several protease-inhibiting domains. This rare
ichthyosiform skin disease is characterized by dry skin,
increased desquamation, hair abnormalities (‘‘bamboo
hair’’), and atopy. A decreased level of functional LEKTI
correlates inversely with SP activity in SC, a decreased
physical barrier function, and severity of the disease.
Another Kazal-type inhibitor is LEKTI-2 (Spink9), which
has been originally discovered in palmar and plantar SC
extracts (Brattsand et al., 2009; Meyer-Hoffert et al., 2009).
LEKTI-2/SPINK9 is mainly expressed in palmar and plantar
skin, close to KLK5. Apart from skin, expression was seen in
the thymus (thus referred as LEKTI-2). All other tissues
showed a very low transcription level of Spink9. LEKTI-2/
SPINK9 selectively inhibited KLK5, but not other proteases
including chymotryptic KLK7 and tryptic KLK14, or several
SPs such as trypsin and chymotrypsin. The LEKTI-2/SPINK9
activity differs in this respect from that of LEKTI-1: The Ki of
LEKTI-2 was found in the range of 60–250 nM. LEKTI-1
domains have been reported to inhibit KLK5 in the range of
3 nM (domain 8–11) to 120 nM (domain 9–15). Further, the
LEKTI-1 domains exhibit a more or less broad activity
spectrum. It remains to be determined whether LEKTI-2/
SPINK9 has a role in skin diseases. Considering the specific
expression of LEKTI-2/SPINK9 at palmar and plantar sites, as
well as its specific activity to inhibit KLK5, it is intriguing to
speculate that it could be a relevant factor in hand and foot
eczema.
By following the hypothesis that likely more Kazal-type
inhibitors are present in human skin, we identified SPINK6 as
a selective inhibitor of KLKs in the skin (Meyer-Hoffert et al.,
2010). Unlike LEKTI-1, but similar to LEKTI-2, SPINK6
possesses only one typical Kazal domain. SPINK6 is strongly
expressed, unlike LEKTI-2, in skin from various locations and
can be purified from human plantar SC extracts. At low
levels, it is expressed in many other tissues and is induced
during KC differentiation. Although immunohistochemical
analyses revealed SPINK6 expression in the SG of healthy
human skin at various anatomical localizations and in the
skin appendages, including sebaceous glands and sweat
glands, SPINK6 expression was found to be decreased in
lesions of atopic dermatitis. Recombinant SPINK6 inhibited
KLK4, KLK5, KLK6, KLK7, KLK12, KLK13, and KLK14, but not
KLK1, KLK3, and KLK11, suggesting a tissue KLK-selective
inhibitory activity, as thrombin, trypsin, plasmin, matriptase,
prostasin, mast cell chymase, cathepsin G, neutrophil
elastase, and chymotrypsin were not inhibited (Meyer-Hoffert
et al., 2010; Kantyka et al., 2011). The finding that SPINK6
inhibited desquamation of human plantar callus in an ex vivo
model suggests that SPINK6 has a role in modulating the
activity of KLKs in human skin. Interestingly, SPINK6
exhibited some proteolytic inhibitory activity against cas-
pase-14 and is so far the only reversible inhibitor of caspase-
14 in human skin (Kantyka et al., 2011).
Trappins and SERPINS of human skin
Apart from LEKTIs, KC produce a number of additional
protease inhibitors. Members of one group are termed
‘‘trappins’’ (acronym for transglutaminase substrate, WAP-
domain-containing proteins; Schalkwijk et al., 1999). Human
epidermis contains secretory leukocyte protease inhibitor and
elafin. Both are efficient inhibitors of neutrophil SPs;
secretory leukocyte protease inhibitor inhibits cathepsin G
and elastase, and elafin inhibits elastase and protease-3. This
suggests that these protease inhibitors are important at
inflammatory conditions to protect the tissue from the
damage caused by neutrophil SPs. Moreover, their impor-
tance in wound repair and host defense is well accepted
(Ashcroft et al., 2000; Zhu et al., 2002; Nakamura et al.,
2003).
Another group of SP inhibitors are SERPINs, which
encompass nearly 40 members, of which many have been
implicated in cancer and inflammation (Meyer-Hoffert,
2009b). These protease inhibitors have a unique mechanism
to inhibit enzymatic activity: SERPINs cause a conformational
change of the protease and then covalently bind to it. A few
members of the SERPIN family have been reported to be
expressed in human skin, such as SERPINB3 (squamous cell
carcinoma antigen-1), SERPINB4 (squamous cell carcinoma
antigen-2), and SERPINB13 (headpin/hurpin). SERPINs have
possibly a role in protecting tissue from proteolysis by
bacterial proteases; SERPINB8 and SERPINB9 inhibits sub-
tilisin A. SERPINA1 inactivates some microbial proteases
including protease K. Further, a C-terminal fragment of
SERPINA1 inhibits HIV-1 entry by interaction with the gp41
fusion protein.
Cystatins
Apart from SPs, also cysteine protease activity is under the
control of inhibitors in skin. These include the members of
the cystatine gene family (Zeeuwen et al., 2009). Cystatins
represent polypeptides that are members of a superfamily of
evolutionarily related proteins that can be divided into three
subgroups, and which are widely expressed in several human
tissues and secretions. They effectively inhibit various
cysteine proteases, such as cathepsins B, L, H, K, and S, at
micromolar to picomolar concentrations, in a competitive
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and reversible manner. Whereas cystatin A and cystatin C
were reported to function as epidermal protease inhibitors with
antimicrobial properties—possibly by inhibiting microbial
cysteine proteases—cystatin M/E regulates in the epidermis
crosslinking of structural proteins by transglutaminase 3 in the
cornification process by controlling cathepsin L and legumain
activities (Meyer-Hoffert, 2009b). Cathepsin L has been shown
to activate transglutaminase 3, an epidermis-specific enzyme
that is important in the cornification process where it is
responsible for crosslinking of small proline-rich proteins and
loricrin. A deregulation of this pathway by uncontrolled
cysteine protease activity leads to abnormal SC and dis-
turbance of skin barrier function (Zeeuwen et al., 2009).
Other regulating factors of protease activity
It should not be overlooked that the proteolytic activity of
proteinases depends on factors such as pH and ion
concentration. All SPs including KLKs decrease their proteo-
lytic activity in acidic environments. The physiological
pH of around 5.5 already results in more than 90% less
activity compared with optimal in vitro conditions. Patients
with atopic dermatitis often show an elevated pH at the skin
surface, which might likely contribute to observed elevated
SP levels in these patients (Voegeli et al., 2009, 2011).
Interestingly, the inhibitory activity of LEKTI-1 depends
on the pH as well, which might enhance proteolytic
deregulation when the epidermal pH is elevated. Moreover,
Zn2þ inhibits KLK5 (Debela et al., 2007). This might have
clinical consequences when Zinc levels are low as in
acrodermatitis enteropathica. The exfoliation and inflamma-
tion observed in this disease might be a result of decreased
KLK5 inhibitions.
PROTEASE-ACTIVATED RECEPTORS
Protease-activated receptor (PARs) represent seven mem-
brane-spanning G-protein-coupled receptors that are acti-
vated by SPs, which cleave a ‘‘tethered’’ receptor-activating
ligand at the N terminus (Steinhoff et al., 2005). To date, four
PARs (PAR1–4) have been characterized. PAR-1, PAR-3, and
PAR-4 are activated by thrombin, and PAR-2 by trypsin and
chymotrypsin. In human skin, PAR-2 is abundantly expressed
by KCs (Steinhoff et al., 1999), where it has a role in
regulating permeability barrier homeostasis, inflammation,
pruritus, pigmentation, and wound healing upon activation
by various endogenous and exogenous SPs. Whereas during
skin inflammation, PAR-2 is activated by neutrophil elastase
and mast cell tryptase; upon infection or skin barrier defects,
proteases originating from certain bacteria, house dust mites,
cockroaches, or parasites can activate this receptor (Shpa-
covitch et al., 2007). Activation by Propionibacterium acnes
protease causes induction of certain proinflammatory pro-
teins, matrix metalloproteinases, and antimicrobial peptides,
including LL-37 (Lee et al., 2010).
PROTEASES AND PROTEASE INHIBITORS IN SKIN
DEFENSE
Healthy human skin defends itself by a ‘‘physical defense
shield’’ present in the SC and a layer of various lipids,
together with an acidic pH, and a ‘‘chemical’’ or ‘‘anti-
microbial defense shield’’ of the skin, where location-
dependent different effector systems are activated. In
addition, at the skin surface, defense strategies would be
used, which utilize and control the microflora to prevent
microbial infection by limiting its growth and/or colonization
(Schroder, 2010). It is therefore intriguing to speculate that
healthy skin protects itself at the surface by sequestrating
essential trace elements and inhibiting bacterial proteases,
thus inhibiting, apart from invasion, also degradation of
sensitive antimicrobial peptides at the skin surface.
Upon injury or barrier defects, microbes or microbial
products will come into contact with living epidermal cells,
inducing several innate defense cascades. Among them is
the induction of antimicrobial peptides, in particular, two
b-defensins, preferentially the Gram-negative bacteria killing
hBD-2 and the broad-spectrum antimicrobial peptide hBD-3,
as well as the host-defense peptide cathelicidin hCAP18/LL-
37 (Schroder, 2011). Whereas hBD-2 is mainly induced via
the microbe-associated pattern recognition receptor Toll-like
receptor (TLR) 5, the cathelicidin is induced by injury via
EGFR ligands released upon wounding and 1,25-dihydroxy-
vitamin D3.
Proinflammatory cytokines such as IL-1b, tumor necrosis
factor-a, IL-8, and others will be produced upon acute injury
and infection by KCs, which have been stimulated via
(intracellular) pattern-recognition receptors, mainly the con-
stitutively expressed TLR2 (Miller, 2008). This would induce
the recruitment of neutrophils into the skin, where these
leukocytes accumulate focally within the epidermis and
release proteases such as elastase, cathepsin G, and protease-
3. Keratinocytes within inflamed skin lesions produce
enhanced amounts of elafin and secretory leukocyte protease
inhibitor—which would dampen the activity of neutrophil
proteases. Apart from inducing inflammatory cell recruit-
ment, TLR2 ligands, such as cell wall components of Gram-
positive bacteria, also mediate induction and a further release
of KLK5 in cultured KCs (Yamasaki et al., 2011). In these
conditions, a marked increase of KLK5 activity is seen in KC
supernatants, which implicates a role in vivo—when this
activity is not blocked by KC-derived LEKTI-1, LEKTI-2/
SPINK9, and SPINK6. As a consequence, increased KLK5
activity would cause a temporarily limited, increased
desquamation, which is always seen during healing of banal
skin infections. A summary of the putative role of epidermal
proteases and epidermal protease inhibitors is given in
Figure 1.
PROTEASES AND PROTEASE INHIBITORS IN ROSACEA
A striking picture of rosacea histology is the domination by
irregularly dilated capillary vessels in the upper dermis.
Unlike many bacterial skin infections, the ‘‘epicentre’’ of the
inflammation does not appear to be the pilosebaceous
follicle. The cellular infiltrate, which mainly consists of
lymphocytes, and in papulopustular rosacea also, neutro-
phils, appears to be distributed perivascularly (Crawford
et al., 2004). The observation of dilated capillary vessels in
rosacea lesions suggests the presence of more stimulants for
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vascular endothelial cells, as found for vascular endothelial
growth factor, CD 31, and D2-40 (Yamasaki and Gallo,
2009). A recent study investigating the trigger for enhanced
stimulant expression and subsequent vascular effects identi-
fied the cathelicidin LL37, which induced vasodilatation and
neovascularization in animal models. Effects are mediated
via the formyl peptide receptor-like 1, a G-protein-coupled
receptor expressed on endothelial cells, as well as epidermal
growth factor transactivation. However, there is recent
evidence that some cleavage products of the human
cathelicidin protein hCAP18 have a unique capacity to be
both vasoactive and proinflammatory. Thus, LL37 and other
cathelicidin fragments induce vascular effects through several
signaling pathways and would explain at least parts of the
vascular effects seen in rosacea (Yamasaki and Gallo, 2009).
A further study demonstrated that rosacea patients not only
revealed abnormally high levels of LL-37 but also a different
pattern of LL-37 fragments (Yamasaki et al., 2007). The
principal LL-37 peptide in rosacea, FA-29 and LL-37 itself,
but not the shorter peptides DI-27 and KR-20, which are
abundant in healthy skin, caused erythema and vasodilata-
tion upon injection into mice and have greater proinflamma-
tory properties than the original LL-37 peptide, thus
explaining at least parts of the clinical presentation of this
disease. The presence of the vasoactive and inflammatory
LL-37 peptides in rosacea was explained by abnormal
production of the epidermal KLK5, which cleaves LL-37 into
vasoactive and proinflammatory peptide fragments (Yamasaki
et al., 2007). This, however, does not exclude the possibility
that apart from KLK5, other SPs generate LL-37 peptides in
rosacea. KLK8, recently identified as abundant SP in healthy
skin (Eissa et al., 2011), and KLK14 might have a role in
rosacea besides KLK5. KLK5, KLK8, and KLK14 are induced
upon terminal differentiation and are produced upon terminal
differentiation in the uppermost SG, where LL-37 is also
produced in rosacea (Yamasaki et al., 2007). As dilated
capillary vessels are seen in the upper dermis, one may
speculate that either LL-37 peptides generated in the upper
SG are diffusing down to the upper dermis and/or dermal
KLK(s) contribute to LL-37 proteolysis. The only KLK
produced and released by dermal fibroblasts is KLK14 (Eissa
et al., 2011). The mechanism as to why and how KLK5 is
induced in rosacea was recently investigated by Yamasaki
et al., (2011). They found that ligands of TLR2, a pattern-
recognition receptor that is overexpressed in rosacea, caused
an increase in KLK5 secretion in KCs, which adds another
piece to the puzzle. But what induces LL-37 in rosacea?
Although EGFR ligands are likely candidates, proteases of
different origin might also be candidate molecules inducing
LL-37 and proinflammatory cytokines and matrix metallo-
proteinases via PAR-2 in rosacea (Lee et al., 2010).
A significant association exists between Demodex follicu-
lorum infestation and the development of rosacea. Although
not explicitly shown for Demodex, it is well documented that
house dust mites produce serine and cysteine proteases,
which are known to be involved in the pathogenesis of
allergies. Recent studies revealed that mite-derived SPs, but
not cysteine proteinases, activate KCs via PAR-2 (Kato et al.,
2009), making it possible that LL-37 is also induced by
Demodex SPs in rosacea.
Increased SP activity in rosacea could also be caused by
impaired inhibition. The putatively relevant SP inhibitors
within the epidermis are LEKTI-1 and SPINK6, but not LEKTI-
2/SPINK9 (despite its KLK5-specific inhibition profile),
because of its restricted palmar and plantar expression. There
is yet neither any information about the lesional expression
and activity profile of LEKTI-1 and its cleaved domains, as
well as SPINK6, nor any knowledge about the possible role of
other protease inhibitors (e.g., SERPINs) that could contribute
to increased KLK5 activity in rosacea.
PERSPECTIVE
Today there is strong evidence for a role of proteases, in
particular, the SP KLK5, as key factors in rosacea. KLK5 is
able to activate signaling pathways, which lead to the
production of inflammatory mediators and cytokines and
possibly also epithelial production of the key host-defense
peptide LL-37 (Figure 1). It activates several matrix metallo-
proteases, which cause shedding of several EGFR ligands,
inducing among other proteins also LL-37. The mechanism as
to why KLK5 is enhanced in rosacea is still not fully
understood. A reduced expression of KLK5 inhibitors does
not seem to be the driving mechanism, as patients with
Desquamation
Filaggrin-
processing
Matriptase
Caspase-14
Epidermal protease inhibitors
LEKTI-1, LEKTI-2/SPINK9, SPINK6
HAI-1
Cystatins
SERPINs
Elafin, SLPI
Neutrophil serine proteases
Elastase, proteinase 3, cathepsin G
KLK5,KLK7,
KLK8,KLK14
PAR-2:
inflammation
barrier disruption
hCAP18 processing:
inflammation
Microbial proteases:
P. acnes
Demodex folliculorum
Figure 1. Epidermal proteases and protease inhibitors as regulators of the
skin barrier in healthy and inflamed skin. In healthy skin, matriptase and
caspase-14 are key enzymes for regular filaggrin processing and kallikreins
(KLKs) 5 and 7 (and likely KLK8 and 14) are important for desquamation, thus
forming the regular physical barrier. The activity of these enzymes, which is
timely and spatially different for each enzyme, is controlled by various more
or less specific epidermal protease inhibitors (green box). Apart from these
epidermal proteases, also proteases originating from skin microbes and
parasites get access to living keratinocytes and infiltrating leukocytes, where
they may stimulate proinflammatory cascades (including neutrophil
infiltration) via protease-activating receptors (PARs) and/or cleave the
cathelicidine (hCAP18/LL-37) precursor, which may originate from either
neutrophils and/or keratinocytes, into angiogenic LL-37 fragments, thus
inducing rosacea-relevant processes (blue boxes). HAI-1, hepatocyte growth
factor activator inhibitor-1; LEKTI, lympho-epithelial Kazal-type-related
inhibitor; P. acnes, Propionibacterium acnes; SERPIN, SERine Proteinase
Inhibitor.
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Netherton syndrome, who lack the KLK5 inhibitor LEKTI-1,
do not normally suffer from rosacea. A unique and apparently
rosacea-specific finding is the increased TLR2 expression,
which is absent in other inflammatory skin diseases such as
psoriasis and atopic dermatitis (Yamasaki et al., 2011). TLR2
signaling mediates in KCs induction of KLK5 and, in a 1,25-
dihydroxyvitamin D3-dependent manner, LL-37 (Heilborn
et al., 2010). Thus, it would explain the two key unique
findings in rosacea. But which ligand causes TLR2-dependent
signaling? Sera from rosacea individuals, but not from normal
controls, contained antibodies against heat shock proteins
and lipoproteins from Bacillus oleronius, a bacterium living
in the D. folliculorum gut. As such antigens are known to
represent stimuli for TLRs, it is tempting to speculate about
the involvement of mites in pilosebaceous unit involvement
in rosacea (Yamasaki et al., 2011). Future studies will have to
identify the key factors that initiate inflammatory reactions,
and all the proteases, as well as its regulators, which are
involved in these processes, in rosacea. Doxycycline is an
approved drug for rosacea treatment. It became clear that its
therapeutic potential does not exclusively depend on its
antimicrobial activity but seems to be related more to
protease inhibition (Monk et al., 2011). Specific proteolytic
regulation might have more therapeutic potential in the
future.
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